inPROBE Dx
inPROBE combines photonics and molecular biology to detect HER2 expression in breast cancer, complementing IHC and ISH assays for targeted therapies.
sdsoptic.plCrawled Nov 19, 2026
inPROBE combines photonics and molecular biology to detect HER2 expression in breast cancer, complementing IHC and ISH assays for targeted therapies.
Monoclonal antibodies discovery platform: hybridoma antibody production - up to 30 mg per month manufacturing services
The female breast cancer is the second leading cause of cancer incidence and the fourth leading cause of mortality worldwide, with estimated 2.3 million new cases (11.6% of all cancer) and 666,000 deaths (6.9% of all cancer deaths) in 2022.1
inPROBE enables real-time HER2 detection in cancer, with potential applications for other biomarkers.
Assessing HER2 expression in peritoneal lavage of gastric cancer patients is feasible and may improve the identification of eligible patients for targeted therapy
A peer-reviewed study in *Journal of Visualized Experiments* validates a sandwich ELISA assay by SDS Optic for detecting HER2 in biological samples.
for the assessment of HER2 receptor expression in breast cancer completed in March 2023
SDS Optic S.A. creates medical diagnostic products, including inPROBE, a fiber-optic microsensor for oncology biomarker diagnostics.
The company seeks team members to advance cancer and infectious disease research.
SDS Optic develops cancer diagnostic solutions using advanced optical sensing technologies to detect biomarkers in real time.
Project title: Development of technology for manufacturing easily integrable sensors for detecting physical, chemical, and biological signals. Beneficiary: SDS Optic S.A.
inPPROBE is a new diagnostic technology combining photonics with molecular biology to detect HER2 expression. This point-of-care solution offers the potential to complement immunohistochemistry (IHC) and genetic testing such as in situ hybridization (ISH) to improve access to targeted therapies.